$NWBO News
Last published 2w ago
- 2w agoNWBONorthwest Biotherapeutics Announces Expansion of Its Technical TeamPR NewswireCompany Expanding Key Operational AreasBETHESDA, Md., Oct. 26, 2026 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) NWBio a biotechnology company developing DCVax® personalized immune therapies for solid tumor
- 1mo agoNWBONorthwest Biotherapeutics and the UK National Health Service Blood and Transplant Announce Collaboration to Support DCVax®-L ProductionPR NewswireBETHESDA, Md., Oct. 8, 2026 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor
- 5mo agoHIVEIOVANWBOOTLC+1How Advanced Drug Delivery Could Improve Existing Cancer TreatmentsGlobeNewswireAUSTIN, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: As oncology drug-development costs continue climbing and regulatory pathways become increasingly complex, biotechnology companies are
- 6mo agoCYDYMRNANWBOOTLCCNS Drug Delivery Breakthroughs Unlock Significant Biotech Market OpportunitiesGlobeNewswireAUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the
- 3y agoNWBONorthwest Biotherapeutics Provides Update On Near Term Plans For Submission of Marketing Authorization ApplicationPR NewswireBETHESDA, Md., Oct. 13, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, provided an
- 3y agoNWBONorthwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company's Scientific Advisory BoardPR NewswireBETHESDA, Md., Sept. 12, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announces
- 3y agoNWBONorthwest Biotherapeutics Announces Completion of Prerequisites, and Plans for Submission of Marketing Authorization ApplicationPR NewswireBETHESDA, Md., Aug. 29, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announces that
- 3y agoNWBONorthwest Biotherapeutics and Advent BioServices Announce Receipt of License for Commercial Manufacturing at Sawston, U.K. FacilityPR NewswireOne of the First UK Licenses for Commercial Manufacturing of Cell Therapy Products; Allows Global Delivery of the Products BETHESDA, Md., March 20, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) ("NW
- 3y agoNWBONorthwest Biotherapeutics Announces That It Has No Banking Relationship With SVBPR NewswireBETHESDA, Md., March 11, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today
- 3y agoNWBONorthwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews 2022 Progress and Looks Forward to Strong 2023PR Newswire78% Of All Shares Were Voted; Proposals Received ≥90% of Votes Cast BETHESDA, Md., Jan. 6, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) ("NW Bio"), a biotechnology company developing DCVax®
- 3y agoNWBONorthwest Biotherapeutics Reports Positive Top-Line Results From Phase 3 Trial of DCVax®-L for GlioblastomaPR NewswireBoth Median Survival and "Long Tail" of Extended Survival Were Increased In Both Newly Diagnosed and Recurrent Glioblastoma Results Featured In JAMA Oncology Peer Reviewed Publication BETHESDA, Md., Nov. 17,
- 4y agoNWBONorthwest Biotherapeutics Announces Approval of Pediatric Investigation Plan (PIP) by MHRAPR NewswirePIP Approval Is A Pre-Requisite for Application for Approval of A New Medicine for Adult Patients BETHESDA, Md., Aug. 23, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized
- 4y agoNWBONorthwest Biotherapeutics Announces Filing of Application for License for Commercial Manufacturing at Sawston, UK FacilityPR NewswireApplication Package Developed By Advent BioServices; Builds on Licenses Obtained in 2021 BETHESDA, Md., July 6, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune the
- 4y agoNWBONorthwest Biotherapeutics Announces Presentations On DCVax®-L Personalized Vaccines, Manufacturing and Scale-Up, and DCVax®-L Clinical ProgramPR NewswireBETHESDA, Md., June 5, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported that yesterday on June 4, 2022, in the Industry Expe
- 4y agoNWBOPresentation About Phase 3 Trial of DCVax®-L for Glioblastoma Today At New York Academy of Sciences To Be Available Online As WellPR NewswireBETHESDA, Md., May 10, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported that, as previously announced, a presentation entitl
- 4y agoNWBOPresentation About Phase 3 Trial of DCVax®-L for Glioblastoma To Be Made At New York Academy Of SciencesPR NewswireBETHESDA, Md., May 4, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported that a presentation entitled "Autologous Tumor Lysate
- 4y agoNWBONorthwest Biotherapeutics Announces Commencement Of Cancer Vaccine Production At Its Sawston, UK FacilityPR NewswireBETHESDA, Md., Feb. 17, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced commencement of production of its first dend
- 4y agoNWBONorthwest Biotherapeutics Announces MHRA Approval Of License for GMP Manufacturing At Sawston, UK FacilityPR NewswireBETHESDA, Md., Dec. 21, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that approval has been received from the UK
- 4y agoNWBONorthwest Biotherapeutics Announces $15 Million FinancingPR NewswireBETHESDA, Md., Nov. 29, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced the closing of a $15 million financing on No
- 5y agoNWBONorthwest Biotherapeutics Announces HTA License Issued and MHRA Inspection Conducted for Sawston, UK FacilityPR NewswireBETHESDA, Md., Oct. 28, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced the completion of two key milestones which a
- 5y agoNWBOUK Manufacturing Facility & Phase III Trial Updates From Northwest Biotherapeutics (OTCQB: NWBO)PR NewswireBETHESDA, Md., May 12, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that an application for certification of the
- 5y agoNWBOUK Manufacturing Facility & Phase III Trial Updates From Northwest Biotherapeutics (OTCQB: NWBO)PR NewswireBETHESDA, Md., May 12, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that an application for certification of the
- 10y agoNWBOCenkos Analyst Says He Was Bullied, Harassed Then Forced OutBloombergA Cenkos Securities Plc analyst who left the company amid allegations he had an improper relationship with a drug developer said he suffered a "campaign of harassment" for blowing the whistle on misconduct by senior colleagues.